A safe, simple add-on strategy for lowering HbA1c would be useful for people with type 2 diabetes, especially if it did not require medication changes. This early trial suggests a small glycemic effect, but the clinical importance is uncertain. The short duration, modest HbA1c change, industry sponsorship, and lack of direct human tissue oxygenation or insulin resistance measures limit confidence.
Short 12-week proof-of-concept trial Commercial sponsorship by the ELO water manufacturer Small HbA1c change with no significant week-12 between-group difference in Table 1 No direct human measurements of tissue oxygenation, mitochondrial function, or insulin resistance